undamentalytics Newsletter
Sign in

Liquidia Corp revenue

Liquidia Corp's revenue was $158m in fiscal 2025, up 1031.2% on the year before. Since fiscal 2019 ($8.1m) it has grown at a compound 64.2% a year. Over the last twelve months it was $451m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue8113161714158451
Growth on the year before—−90.8%+>999%+24.0%+9.7%−20.0%+>999%—
Gross profit—11013158——
Gross margin—67.9%76.5%82.1%83.5%58.0%——

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $148M 93.7% —
Services $10M 6.3% ▼ 28.3%

From Liquidia Corp's 10-K filed March 5, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Liquidia Corp $451m 2233.6% 193.7%
Innoviva, Inc. $440m 18.8% 14.9%
Ironwood Pharmaceuticals Inc $389m 26.2% -3.1%
Alvotech $586m 19.7% —
Xeris Biopharma Holdings, Inc. $335m 36.3% 35.8%
Evolus, Inc. $316m 13.9% 23.4%

Compare with peers

Head to head: INVA vs LQDAIRWD vs LQDAALVO vs LQDA

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Liquidia Corp's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Liquidia Corp.